Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Hidden Gems ShareCafe Investor Webinar (June 2020)
18 slides from Kazia Therapeutics's conference presentation, Jun 26, 2020
Slide 1: Kazia presents to Hidden Gems ShareCafe Investor Webinar
ASX RELEASE 25 June 2020 KAZIA PRESENTS TO HIDDEN GEMS SHARECAFE INVESTOR WEBINAR Sydney, 25 April 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation to be made by our CEO, Dr James Garner
Slide 2: About Kazia Therapeutics (continued)
common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxalisib was granted orphan designation for glioblastoma by
Slide 3: A company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Presentation to ‘Hidden Gems’ ShareCafe Investor Webinar Dr James Garner Chief Executive Officer 26 June 2020 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 5: Investment Rationale
Investment Rationale Our lead program, paxalisib, was designed by Genentech, and is being 1 developed for glioblastoma, the most common form of brain cancer, where the only available drug is ineffective for two-thirds of patients Paxalisib has shown strong evidence of efficacy in an ongoing phase II
Slide 6: Treatment of brain cancer has improved little in recent decades, unlike other cancers
Treatment of brain cancer has improved little in recent decades, unlike other cancers Brain Cancer 1990s 2000s 2010s (glioblastoma) Lung 1990s 2000s 2010s Cancer 3
Slide 7: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 8: Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases
Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond Paxalisib is being developed for t
Slide 9: PI3K class is well-validated, but GDC-0084 is unique in crossing the blood-brain barrier
PI3K class is well-validated, but GDC-0084 is unique in its ability to cross the blood-brain barrier Zydelig (idelalisib) Aliqopa (copanlisib) Copiktra (duvelisib) Piqray (alpelisib) Paxalisib FDA Approved FDA Approved FDA Approved FDA Approved In phase II human trials July 2014 ✓ September 2017 ✓ O
Slide 10: New phase II data compares favourably to historical data for temozolomide
New phase II data compares favourably to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) Part A + Part B (n=30) Part A (n=9) Paxalisib 8.5 months Paxalisib 17.7 months Median PFS Median OS Existing 5.3 months Existing 12.7 months The
Slide 11: Brain cancer represents a significant commercial opportunity for paxalisib
INDICATIVE Brain cancer represents a significant commercial opportunity for paxalisib, with limited competition Path to Market Expansion Opportunities ‘Blue Sky’ Potential Brain Metastases Glioblastoma (secondary brain cancer) Other Adult Other Cancers with Primary Brain Disordered PI3K 12,500 Cance
Slide 12: Six ongoing clinical trials across two assets
Six ongoing clinical trials across two assets, lead program covers full range of brain cancers GDC-0084 Cantrixil Primary Brain Cancer Secondary Brain Cancer Ovarian (brain cancer that begins in the brain) (brain cancer that spreads from elsewhere in the body) Cancer Glioblastoma DIPG Brain Breast B
Slide 13: Kazia has delivered all milestones to date, with multiple data read-outs expected
Kazia has delivered all milestones to date, with multiple data read-outs expected over 6-12 months ✓ ✓ ✓ ✓ ✓ Commence Commence Interim Data Interim Data Interim Data Interim Data Interim Data Paxalisib NCI-funded phase 1 study from phase 1 from phase 2 from phase 2 from phase 1 from phase 2 phase 2
Slide 14: Recent institutional placement leaves the company well funded
Recent institutional placement leaves the company well funded through current economic uncertainty Share Price (AU$) KZA 0.80 Market Capitalisation ~AU$ 40 million 0.70 NASDAQ: KZIA (1:10 ratio) Listing 0.60 ASX: KZA 0.50 Successful placement in April 2020 Current Assets $7.5 million 0.40 (31 Decemb
Slide 15: The partnering market for new oncology drugs is active and driven by emerging data
The partnering market for new oncology drugs is active and driven by emerging data Select CY2019 Licensing Transactions Licensee Licensor Stage Asset(s) Deal Value (US$) Discovery Lipid kinase inhibitors $470M Preclinical Anti-CD38 antibody $275M Preclinical RAS-RAF-MAPK inhibitors $207M Clinical ME
Slide 16: CY2020 will be an exciting period for Kazia, and a crucial inflection point
CY2020 will be an exciting period for Kazia, and a crucial inflection point for our programs 3Q CY2020 Interim data from phase I study of paxalisib in DIPG (provisional) 3Q CY2020 Interim data from phase II study of paxalisib in BCBM (provisional) 3Q CY2020 Annual Report 2H CY2020 Commencement of re
Slide 17: For further information…
For further information… http://www.KaziaTherapeutics.com [email protected] Kazia will be presenting at the American Association of Cancer Research (AACR) Annual Meeting AACR Virtual Annual Meeting II 22 – 24 June 2020 Free to register via www.aacr.org 14
Slide 18: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — Hidden Gems ShareCafe Investor Webinar (June 2020) on 6ix